Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic ...
A single injection of the drug lepodisiran slashed a key heart risk factor, lipoprotein(a), by 94% for six months, offers hope for treating a genetic cause of heart disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results